Hims & Hers Health Gestione
Gestione criteri di controllo 2/4
Hims & Hers Health Il CEO è Andrew Dudum, nominato in Jan2017, e ha un mandato di 7.83 anni. la retribuzione annua totale è $ 14.40M, composta da 4.2% di stipendio e 95.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 8.68% delle azioni della società, per un valore di $ 444.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 2.9 anni.
Informazioni chiave
Andrew Dudum
Amministratore delegato
US$14.4m
Compenso totale
| Percentuale dello stipendio del CEO | 4.2% |
| Mandato del CEO | 7.8yrs |
| Proprietà del CEO | 8.7% |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 2.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Compensazione vs Mercato: La retribuzione totale di Andrew ($USD 14.40M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.92M ).
Compensazione vs guadagni: La retribuzione di Andrew è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Andrew Dudum (35 yo)
7.8yrs
Mandato
US$14,401,411
Compensazione
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$14.40m | 8.68% $ 444.1m | |
| Chief Financial Officer | 2.8yrs | US$7.43m | 0.067% $ 3.4m | |
| Chief Operating Officer | 3.8yrs | US$6.77m | 0.29% $ 14.8m | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$5.21m | 0.078% $ 4.0m | |
| Chief Medical Officer | 1.9yrs | US$198.26k | 0.097% $ 5.0m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.089% $ 4.5m | |
| Senior VP | 5.4yrs | US$961.12k | 0.0023% $ 119.7k | |
| Chief Communications Officer | 1.1yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Human Resources | 2.7yrs | Nessun dato | Nessun dato | |
| Senior VP & Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Chief Pharmacy & Innovation Officer | 1.9yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Mental Health | 1.7yrs | Nessun dato | Nessun dato |
2.7yrs
Durata media
44yo
Età media
Gestione esperta: Il team dirigenziale di HIMS è considerato esperto (durata media dell'incarico 2.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 3.8yrs | US$14.40m | 8.68% $ 444.1m | |
| Chief Medical Officer | 2.8yrs | US$198.26k | 0.097% $ 5.0m | |
| Senior VP & Member of Medical Advisory Board | 2.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 4.2yrs | US$194.26k | 0.025% $ 1.3m | |
| Lead Independent Director | 4.2yrs | US$227.41k | 0.090% $ 4.6m | |
| Independent Director | 3.7yrs | US$205.51k | 0.033% $ 1.7m | |
| Member of Medical Advisory Board | 2.9yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 2.9yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 2.9yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 2.9yrs | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | 2.9yrs | Nessun dato | Nessun dato |
2.9yrs
Durata media
53yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di HIMS non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.